en · de · es · pt
peptide-index.peptides5388.com › Blog › Sr9009 Background And Mechanism — Worked Examples

Sr9009 Background And Mechanism — Worked Examples

By Editorial Desk · published 2025-08-06 · last reviewed 2025-08-29 · Blog

A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-08-29. Anything still debated is marked as such rather than presented as settled.

SR9009 Background and Mechanism

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

Background and Receptor Mechanism

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small-molecule REV-ERB agonistNot a hormone or natural product
Primary targetsREV-ERBα and REV-ERBβNuclear receptors involved in circadian and metabolic regulation
AppearanceWhite to off-white solidTypical for purified research samples
SolubilitySoluble in DMSO and ethanol; low water solubilityLaboratory solubility depends on solvent and purity
Common synonymsSR9009; StenabolicStenabolic is a colloquial name, not a formal chemical name

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Related pages on this site

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

SR9009 Identity and Mechanism

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

Supporting material

Approximately one month after the attacks, the United States led a broad coalition of international forces to overthrow the Taliban regime from Afghanistan for their harboring of al-Qaeda. Though Pakistani authorities were initially reluctant to align themselves with the U.S. against the Taliban, they permitted the coalition access to their military bases, and arrested and handed over to the U.S. more than 600 suspected al-Qaeda members. In 2011, the U.S. and NATO under President Obama initiated a drawdown of troops in Afghanistan finalized in 2016. During the presidencies of Donald Trump and Joe Biden in 2020 and 2021, the United States alongside its NATO allies withdrew all troops from Afghanistan, completing the withdrawal of all regular U.S. troops on August 30, 2021. The withdrawal marked the end of the 2001–2021 war in Afghanistan. Biden said that after nearly 20 years of war, it was clear that the U.S. military could not transform Afghanistan into a modern democracy.

==== Custom manufacturing ==== The products and services offered by the fine chemical industry fall into two broad categories: (1) "Exclusives" or custom manufacturing (CM) and (2) "standard" or "catalogue" products. "Exclusives", provided mostly under contract research or custom manufacturing arrangements, prevail in business with life science companies; "standards" prevail in other target markets. Service-intense custom manufacturing constitutes the most prominent activity of the fine chemical industry. Custom manufacturing is the antonym of outsourcing. In custom manufacturing, a specialty-chemicals company outsources the process development, pilot plant, and industrial-scale production of an active ingredient, or a predecessor thereof, to one, or a few, fine chemical companies. The intellectual property of the product, and generally also the manufacturing process, stay with the customer. The customer-supplier relationship is governed by an exclusive supply agreement. At the beginning of cooperation, the customer provides a "tech package" which, in its simplest version, includes a laboratory synthesis description and SHE recommendations. In this case, the whole scale up, which comprises a factor of about one million (10 gram → 10 ton quantities), is done by the fine chemical company.

Clobazam, sold under the brand names Frisium and Onfi, among others, is a long-acting benzodiazepine medication primarily used as an anxiolytic and anticonvulsant. Clobazam is a 1,5-benzodiazepine with unique pharmacological characteristics that was patented in 1968. Clobazam was first synthesized in 1966 and first published in 1969. It was approved in Australia in 1970 and France in 1974 for short-term anxiety management. Clobazam is solely approved for use in the United States as a treatment for Lennox–Gastaut syndrome, but the drug is available in other countries as an anti-anxiety agent for the short-term treatment of persistent and debilitating forms of anxiety. It has shown a distinct profile and addictive potential compared to the more common benzodiazepines. Clobazam is the only 1,5‑benzodiazepine that has been marketed for clinical use, making it the sole representative of this structural class of benzodiazepines. The drug has been approved by Health Canada as an add-on therapy for generalized tonic–clonic, myoclonic, and focal impaired awareness seizures. In 2011, Lundbeck markets the drug in the United States as Onfi, an adjunctive therapy for seizures associated with Lennox–Gastaut syndrome in patients who are at least two years old.

An electrophilic cyclization occurs in step 5, and an intramolecular proton transfer attacks the taxenyl cation (step 6). This forms the fused ring structure intermediate known as taxadiene. Taxadiene then undergoes a series of 10 oxidations via NADPH, forming the intermediate taxadiene-5α-acetoxy-10β-ol (multiple steps later in the figure). A series of hydroxylations and esterficiations occur, forming the intermediate 10-deacetyl-baccatin III, which undergoes a further series of esterifications and a side-chain hydroxylation. This finally yields the product paclitaxel.

Placing workers at the heart of changes made, including through workers being placed on company boards The implementation of a "right to disconnect" to prevent AI-enabled remote working from creating an "always-on" culture. Attaching "good work" conditions to public funding for AI research and development. The TUC has also drafted a model Artificial Intelligence (Regulation and Employment Rights) Bill, designed to fill the regulatory gap left by the UK's divergence from EU data protection standards and the absence of a domestic equivalent to the EU AI Act. Prospect, the union representing scientists, engineers, and tech workers, has campaigned for civil servants and technical professionals to have a voice in the rollout of AI. Prospect has highlighted the risks of an "always-on" culture, of the prevalence of workplace surveillance, and the need for workers to have ownership over the data collected about them by their employers.

Sources: en.wikipedia.org

Supporting material

== Awards == Advance for Medical Laboratory Professionals received the Corporate Recognition Award from the Pennsylvania chapter of the American Society for Clinical Laboratory Science. In 2006, the trade journal's editor, Matthew Patton, won an award in the Awards for Publication Excellence in the Editorial and Advocacy Writing category

== Principle of operations == In peptide biosensors, peptides serve as the selective recognition element due to their amino acid sequence, which also accounts for their tailored binding affinity and specificity towards various analytes. When the analyte interacts with the peptide recognition elements via non-covalent interactions, this interaction produces a change that can be transduced into a measurable signal. Peptides on their own cannot generate a quantifiable signal after binding events with the analytes, they must be bio-conjugated to signal markers. Common detection strategies include optical methods such as fluorescence resonance energy transfer (FRET), electrochemical outputs such as change in current, impedance, or potential, and sometimes mechanical or piezoelectric signals if the peptide-analyte binding alters mass or surface properties. These methods are commonly employed due to their sensitivity and compatibility with small peptide-based interfaces

The mRNA is loaded onto the ribosome and is read three nucleotides at a time by matching each codon to its base pairing anticodon located on a transfer RNA molecule, which carries the amino acid corresponding to the codon it recognizes. The enzyme aminoacyl tRNA synthetase "charges" the tRNA molecules with the correct amino acids. The growing polypeptide is often termed the nascent chain. Proteins are always biosynthesized from N-terminus to C-terminus. The size of a synthesized protein can be measured by the number of amino acids it contains and by its total molecular mass, which is normally reported with the unit dalton (Da), or its derivative unit kilodalton (kDa). The average size of a protein increases from Archaea to Bacteria to Eukaryote (283, 311, 438 residues and 31, 34, 49 kDa respectively) due to a bigger number of protein domains constituting proteins in higher organisms. For instance, yeast proteins are on average 466 amino acids long and 53 kDa in mass. The largest known proteins are the titins, a component of the muscle sarcomere, with a molecular mass of almost 3000 kDa and a total length of almost 27000 amino acids.

Sponges lack a digestive, circulatory, respiratory, or excretory system. Instead, they rely on the flow of water through their bodies to perform these functions. Many have adapted a hollow structure to facilitate the flow of water through their bodies. They typically feed by drawing in water through pores, filtering out small particles of food. They absorb oxygen dissolved in water, and they release carbon dioxide and nitrogenous waste into water that flows through them. Sponges can reproduce sexually and asexually. Asexual reproduction happens through a variety of mechanisms including by fragmentation, where a piece of the sponge splits off and reestablishes somewhere else. For sexual reproduction, most sponges are hermaphrodites, they produce both egg and sperm cells.

Actress Cherylee Houston has hypermobile EDS. She uses a wheelchair and was the first full-time disabled actress on Coronation Street. Drag queen Yvie Oddly, winner of the 11th season of RuPaul's Drag Race Eric the Actor, a regular caller to The Howard Stern Show Actress and activist Jameela Jamil Writer and actress Lena Dunham Australian singer Sia Singer Halsey YouTuber and disability rights activist Annie Elainey Miss America 2020 Camille Schrier Baroque flautist, musicologist, and broadcast classical music presenter Hannah French Deaf singer/songwriter Mandy Harvey YouTuber and disability rights activist Jessica Kellgren-Fozard Singer-songwriter, author and artist Martha Marlow Pornographic actor and writer Lorelei Lee Reality show contestant Trevor Jones, dead from the vascular form of the disorder Scrunchie creator Rommy Hunt Revson, dead from a ruptured aorta Japanese voice actress and singer Tomori Kusunoki Chaz Lucius, an American former professional ice hockey player

Sources: en.wikipedia.org

Supporting material

== Society and culture == Methocarbamol was approved as a muscle relaxant for acute, painful musculoskeletal conditions in the United States in 1957. Muscle relaxants are widely used to treat low back pain, one of the most frequent health problems in industrialized countries. Currently, there are more than 3 million prescriptions filled yearly. Methocarbamol and orphenadrine are each used in more than 250,000 U.S. emergency department visits for lower back pain each year. In the United States, low back pain is the fifth most common reason for all physician visits and the second most common symptomatic reason. In 80% of primary care visits for low back pain, at least one medication was prescribed at the initial office visit and more than one third were prescribed two or more medications. The most commonly prescribed drugs for low back pain included skeletal muscle relaxants. Cyclobenzaprine and methocarbamol are on the U.S. Medicare formulary, which may account for the higher use of these products.

=== "One Strike and You're Out" policy" === Scholars have argued that Clinton's policies came in an attempt to swing back the tide of white voters who had left the party two decades earlier to support Reagan. The Clinton administration articulated that the policies were an attempt to be fiscally conservative and to slash the federal budget deficit. During the administration, the federal budget saw a reduction in public housing funding by $17 billion. The federal corrections programs received a $19 billion, which a 61 percent decrease in public housing funding and a 171 percent increase in federal prison budgeting. Scholars argue that the construction of federal prisons replaced the major public housing programs for the urban poor. Clinton's "One Strike and You're Out" policy stated, "From now on, the rule for residents who commit crime and peddle drugs should be one strike and you're out." Any tenant of public housing convicted of any drug-related offence would no longer have access to public housing.

Although originally raised for their feathers in the 19th century, ostriches are now more popular for both meat and leather. Ostrich leather has a characteristic "goose bump" look because of the large follicles where the feathers grew. Different processes produce different finishes for many applications, including upholstery, footwear, automotive products, accessories, and clothing. In Thailand, stingray leather is used in wallets and belts. Stingray leather is tough and durable. The leather is often dyed black and covered with tiny round bumps in the natural pattern of the back ridge of an animal. These bumps are then usually dyed white to highlight the decoration. Stingray rawhide is also used as grips on Chinese swords, Scottish basket hilted swords, and Japanese katanas. Stingray leather is also used for high abrasion areas in motorcycle racing leathers (especially in gloves, where its high abrasion resistance helps prevent wear through in the event of an accident). For a given thickness, fish leather is typically much stronger due to its criss-crossed fibers.

=== Safety === The gap between recommended daily intake and what are considered safe upper limits (ULs) can be small. For example, for calcium the U.S. Food and Drug Administration set the recommended intake for adults over 70 years at 1,200 mg/day and the UL at 2,000 mg/day. The European Union also sets recommended amounts and upper limits, which are not always in accord with the U.S. Likewise, Japan, which sets the UL for iodine at 3000 μg versus 1100 for the U.S. and 600 for the EU. In the table above, magnesium appears to be an anomaly as the recommended intake for adult men is 420 mg/day (women 350 mg/day) while the UL is lower than the recommended, at 350 mg. The reason is that the UL is specific to consuming more than 350 mg of magnesium all at once, in the form of a dietary supplement, as this may cause diarrhea. Magnesium-rich foods do not cause this problem.

Early in 1953 Watson and Crick proposed a correct structure for the DNA double helix. Pauling later cited several reasons to explain how he had been misled about the structure of DNA, among them misleading density data and the lack of high quality X-ray diffraction photographs. Pauling described this situation as "the biggest disappointment in his life". During the time Pauling was researching the problem, Rosalind Franklin in England was creating the world's best images. They were key to Watson's and Crick's success. Pauling did not see them before devising his mistaken DNA structure, although his assistant Robert Corey did see at least some of them, while taking Pauling's place at a summer 1952 protein conference in England. Pauling had been prevented from attending because his passport was withheld by the State Department on suspicion that he had Communist sympathies. This led to the legend that Pauling missed the structure of DNA because of the politics of the day (this was at the start of the McCarthy period in the United States). Politics did not play a critical role. Not only did Corey see the images at the time, but Pauling himself regained his passport within a few weeks and toured English laboratories well before writing his DNA paper. He had ample opportunity to visit Franklin's lab and see her work, but chose not to. Despite these times, Pauling chose to move on from them and be thankful for the discoveries that he had already found.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

How does SR9009 work?

It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.

Is SR9009 proven to improve human performance?

No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Network